zimmer biomet gain toehold turnaround
firm wide moat give leg restor growth large-
integr biomet full pitfal
appreci upsid remain
zimmer biomet brought self-
supply-chain inventori
scenario analysi zimmer biomet
conduct analyst govern
code ethics/cod conduct polici
secur trade polici equival
invest research polici inform
regard conflict interest pleas visit
think zimmer biomet turnaround take hold moder rais fair valu estim
per share reflect optimist expect long-term growth three year ago
wide-moat firm fell tailspin follow tangl food drug administr
defici supply-chain inform system led product shortag face
challeng put stress organ legaci biomet zimmer workforc devolv
hanson step ceo role tackl chao zimmer biomet inventori restor
appropri level manufactur facil remedi come close firm readi
play catch-up placement rosa robot
zimmer biomet continu benefit high switch cost among orthoped surgeon support
wide econom moat firm recent challeng havent fundament driven away surgeon
train instrument devic
hanson abl amelior underli fissur zimmer biomet cultur
kept combin firm mount organ coordin plan address regulatori
inventori issu
rel pure play orthoped reli disproportion large-joint reconstruct
anticip zimmer biomet see signific impact entri orthoped robot
compar key competitor
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
zimmer biomet brought self-inflict error
grappl multipl unforc error drag perform sinc late
zimmer biomet turn corner new manag put fire implement
new growth driver confid ceo bryan hanson effort put firm back feet
lead stronger return sharehold long term
three year ago zimmer biomet hit low pointwith regulatori challeng glitch supply-
chain manag result inventori shortag grow backlog turn left sale
rep less motiv sell cascad oper problem also quickli led finger-point
legaci biomet zimmer workforc underscor rift differ
corpor cultur exhibit firm timelin sinc zimmer close biomet deal mid-
overal think zimmer biomet pois acceler sale growth thank adequ stock
key product remedi effort fulli address regulatori concern strong line-up new
technolog perhap import think transit new ceo hanson initi progress
set stage zimmer biomet return fight form
throughout zimmer biomet stop start return modicum oper
compet weve consist held wide econom moat remain intact
orthoped devic maker zimmer biomet econom moat stem primarili switch cost
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
orthoped surgeon secondarili intang asset includ intellectu properti proprietari
manufactur know-how sale rep relationship practition
examin issu hinder zimmer biomet recent perform think
regulatori oper defici detract firm wide moat still think
zimmer biomet sizabl competit advantag sustain long term
high switch cost remain intactsurgeon still face long-stand lengthi learn curv
master one compani proprietari instrument implant order deliv optim patient
outcom surgeon invest time master keep skill one tool set
typic reluct switch competit brand would need climb learn
curv entail take time retrain time could otherwis revenue-
gener sinc could see patient time practic patient gain comfort facil
tool devic final potenti put patient clinic risk period
lower familiar
also weve seen littl way signific organ share gain among major
competitor zimmer biomet johnson johnson smith nephew histor
perspect signific last share gain come mainli acquisit even
competitor fall behind other technolog front long devic maker launch
compar product within three four year bare bobbl detect market share movement
instead far like surgeon train one brand instrument will stick
brand compar new technolog launch
thu name game captur mani surgeon possibl train becom
comfort one brand instrument provid high-touch respons servic
remain brand surgeon stick prefer implant vendor sale rep
beyond year use vendor orthoped procedur
zimmer biomet remain strong competit posit term surgeon estim zimmer
biomet pool orthoped surgeon train instrument stryker share
closer roughli top-tier competitor remain midtier
compani smith nephew project close orthoped surgeon pool
recent aggress push place mako robot think gain
market share knee made inroad competit surgeon believ rel
strong share gain compar competit dynam past year know
stryker knee implant volum grow ahead market manag indic
competit surgeon train mako exhibit estim market share
said knee market share estim base dollar rather volum
competitor consist report dollar figur consid note product mix shift
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
seen toward premium-pric cementless knee wake mako robot placement think
may inflat appar share shift degre
howev clear whether recent share gain durabl zimmer biomet
manag said competit surgeon train mako difficult
discern much activ driven gener surgeon interest investig trial
robot technolog robot avail major orthoped devic maker
whether competit surgeon commit adopt mako princip brand
point base competit dynam weve observ time inclin believ
despit mako novelti attract notic attent competit surgeon zimmer biomet
good shot win back surgeon rosa robot even train mako
asid high switch cost intang asset includ intellectu properti sale rep
relationship practition ancillari moat sourc weve seen littl suggest
pillar zimmer biomet wide moat chang acknowledg intellectu properti
medic devic strong moat sourc pharmaceut biotech firm often
engin way around differ solut featur exampl haptic control mako
robot prevent surgeon cut beyond predetermin area proprietari zimmer
biomet rosa robot featur differ proprietari function dynam track allow
robot move along patient surgeon test rang motion throughout joint
replac procedur end intellectu properti provid moder protect competit
devic maker rival tend defend ip aggress often greater incent
supply-chain inventori manag snafu iron
origin issu poor supply-chain integr led shortag key product combin firm
began cross-sel product late issu surfac late third-quart
 johnsonsmith johnsonsmith nephewoth page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
manag indic shortag biomet oxford unicompartment knee legaci biomet hip
legaci zimmer persona knee instrument damp sale growth product line
manag focus retain two salesforc prepar cross-sel
inform technolog aspect supply-chain manag legaci zimmer biomet put
back burner meantim zimmer biomet jury-rig interim system pull order
product inventori inform share drive consolid one spreadsheet
rippl effect hiccup inventori emerg sale rep less confid
could fulfil order surgeon reluct assert sell haze
uncertainti meantim back order began grow sale rep becam demor
increasingli disappoint custom
difficult fault former zimmer biomet ceo dvorak focus first preserv
integr salesforc follow back-offic oper slower process move singl
supply-chain inform system clearli caught firm year acquisit
close perhap surpris quickli inventori situat worsen
would take anoth eight quarter resolv recogn transit c-suit
eight quarter ad anoth challeng resolv firm issu like slow whole
process nonetheless took two year rectifi suppli shortfal far longer two
quarter dvorak suggest situat initi came light
current situat begin inventori level restor back order
fallen also help renew salesforc appetit sell provid high-touch servic
come orthoped product today inventori back normal level firm abl
shift focu seek supply-chain effici expect area optim
sever reason first largest manufactur hip knee implant zimmer biomet good
posit flex buy power come sourc materi work vendor
machin tool firm special orthoped second hanson discuss
issu ration zimmer biomet wide-rang portfolio interest simplifi supply-chain
manag improv servic across smaller spectrum product project
manag began tackl play project basi point
oper margin expans end
origin issu fourth quarter fda conduct routin inspect legaci
biomet plant known north campu facil file outlin
observ word fda specifi condit may violat feder law
govern manufactur orthoped implant
compar redact weve seen issu medic devic firm year
one substanti extens seriou exampl fda rais issu water
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
sampl fail meet accept microbi endotoxin toler possibl
particul contamin clean room perhap troubl
fda alreadi rais number issu least two year earlier base
fda assess firm adequ resolv issu continu ship
product manufactur condit period
mani issu medic devic maker weve review common issu
relat qualiti controlspecif document process procedur place ensur
quality-rel aspect product manufactur thu remedi usual involv revis
process retrain employe unusu experi see specif issu rais
direct implic steril manufactur product exampl found
zimmer biomet worrisom expect would take time fulli
address regulatori issu seem like chang would need made
physic plant addit common observ qualiti process
current situat zimmer biomet made chang address regulatori concern north campu
facil reinspect fda april disappoint though necessarili
surpris reinspect fail give legaci biomet plant clean bill health consid
extens seriou origin observ put regulatori issu
bed would consider endeavor
particular fda reiter origin observ respons zimmer biomet disput
find indic miscommun chang
implement nevertheless difficult win argument fda firm wise
turn attent past month make chang fulli allay regul concern
end third-quart manag indic remedi effort reach point
complet would allow engin shift work qualiti problem
alloc time research develop go forward
expect reinspect north campu though exact time fda alway
difficult estim prepar next reinspect zimmer biomet use third-parti
organ conduct mock audit north campu think effort underscor
serious new manag team taken regulatori challeng
separ think import recogn never result product
recal ship-hold halt product north campu facil addit fda
institut hold zimmer biomet product file market approv
pathway view factor favor
iron howev initi effort redress fda observ actual exacerb
inventori shortag revis manufactur process document revolv around
retrain employe slow product coupl quarter
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
firm qualiti begin program ground think retrain taken hold
longer slow product
integr biomet full pitfal
origin issu differ zimmer biomet cultur made challeng get employe
combin compani work togeth
think inventori issu one aspect larger challeng integr biomet
two compani cultiv differ somewhat diametr oppos corpor
cultur complic issu keep mind biomet found two zimmer
employeesdan miller jerri fergusonbrok away zimmer pursu believ
superior technolog entrepreneuri flexibl encourag environ thu
import rememb biomet stori origin built founder reject
buttoned-up bureaucrat organ zimmer believ stifl innov
zimmer equival profession suit biomet employe felt comfort
wear blue jean think box come rapid innov allow biomet
punch weight compar larger competitorsoff meaning innov
garner solid reput high-qual engin close relationship surgeon
contrast zimmer cultur center around conserv choic perspect
zimmer ceo david dvorak previous firm gener counsel play integr
role negoti settlement depart justic high-profil industri investig
kickback firm gener stuck knit orient like play role
zimmer acquisit larg fell line firm alreadi offer exampl purchas
abbott spine augment zimmer exist portfolio knee creation provid surgeon
minim invas arthroscop treatment option knee patient
cultur differ also manifest execut compens polici founder dane
miller proud earn salari bonu per year option biomet
compar nearli million former ceo ray elliott earn zimmer biomet big
famili type cultur reflect biomet employe grant stock option
asid miller three found partner salari worker receiv first day
hourli worker would receiv stock option two year everi five year
though miller end retir ceo posit biomet due differ
board navig secular malais affect entir orthoped industri
remain much-rev figur biomet follow privat equiti buy-out biomet miller
purchas ownership newli privat entiti note miller vote reject buy-out
zimmer character impend deal pain wouldnt surpris biomet
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
current situat pleas see hanson meet challeng weav two differ
organ blend cultur tap biomet strength orthoped innov
zimmer fort market manufactur hanson come two year sinc took
ceo role januari tenur preced roughli six-month period
former cfo florin appoint interim ceo former ceo dvorak resign abruptli mid-
disrupt c-suit like contribut gener dysfunct
emerg late
weve long impress hanson oper chop charismat leadership sinc day
variou posit covidien consist deliv result rose rank
follow acquisit covidien hanson led minim invas therapi group
hous highli engin legaci covidien product includ energi devic surgic
solut consid depth experi devic sale medic devic regul chang
manag covidien hanson well equip run devic manufactur opinion
particularli well suit zimmer biomet partli come outsid orthoped industri
thu neutral leader zimmer biomet
sinc earli hanson restor adequ stock inventori within month overseen on-going
remedi effort north campu facil stabil relationship key custom heal
cultur divis hamper combin entiti
importantli asid restor order immedi situat hanson kept develop
regulatori approv rosa robot track order hit goal soft launch earli
commerci rosa put zimmer biomet strong posit offer altern mako
begin build instal base robot point place mako robot
 estim pool american hospit suffici orthoped volum support
robot approxim think room zimmer biomet establish
major robot provid firm also benefit secular trend grow practition interest
adopt robot technolog strong posit leverag base orthoped surgeon
train zimmer biomet instrument larger either rosa
clearli critic firm return growth given zimmer biomet posit orthoped pure
play heavili reliant large-joint reconstruct account roughli total revenu rosa
adopt implant pull-through translat robust growth
detail discuss orthoped robot pleas see page robot invad
zimmer biomet share appreci upsid remain
rais zimmer biomet fair valu estim per share reflect
optimist project match market growth larg joint slightli higher longer-
term earn growth think turnaround effort begun take hold project
knee volum reach growth price eros hover around annual
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
put knee growth line market translat total annual revenu growth
estim averag annual oper incom growth firm benefit
pull-through higher-margin devic consum associ rosa robot effort
increas effici longer term well decreas restructur charg five year
would put oper profit shi zimmer histor level low
scenario analysi zimmer biomet
bullish assumpt put zimmer valu per share incorpor robust
knee hip volum growth outpac market respect thank better-
than-expect uptak rosa robot smaller price declin result growth outpac
market mid-single-digit growth also assum averag annual growth extrem
trauma along mid-single-digit growth dental surgic product zimmer
fulli resolv oper regulatori issu push consolid oper margin beyond
basi point past peak level low think upsid zimmer biomet share
think key risk assumpt center around rosa robot technolog well
receiv surgeon could crimp zimmer biomet abil return market growth knee
point less concern long-term clinic valid robot take anoth
five year determin concern surgeon wont embrac rosa particular
featuresdynam track abil use saw surgeon choic lack ct imag soft-
tissu balanc guidancewhich would leav good posit attract competit
surgeon sens practition percept rosa within next month
anoth risk short-term outcom rosa compar mako clinic
data mako suggest robot associ less post-operative pain less opiate-bas
medic post-operative pain less physic therapi significantli shorter hospit stay
anticip short-term data rosa clinic outcom could arriv three five year
assumpt bake bearish scenario peg zimmer biomet per
share scenario see anem market adopt rosa robot weaker large-joint
implant product pull-through declin price almost complet off-set volum gain
hip knee trauma extrem see averag annual growth dental spine
surgic product declin low singl digit zimmer oper margin peak
thank unfavor price wholli off-set lower sale market
page
page
page
page
page
page
page
page
zimmer biomet gain toehold turnaround jan import disclosur end report
